Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Telix Pharmaceuticals updates investors as first patient is dosed in phase 3 prostate cancer trial

Telix Pharmaceuticals updates on its prostate cancer Phase 3 trial, dosing the first Part 2 patient and outlining regulatory ...
Nasdaq

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.
Seeking Alpha

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely

Discover how Pelthos Pharmaceuticals’ Zelsuvmi launch drives rapid revenue growth and market expansion. Click here to read my ...
Benzinga.com

What to Expect from Kiniksa Pharmaceuticals's Earnings

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly earnings on Tuesday, 2025-10-28. Here's a brief overview of what investors should keep in mind before the announcement.

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders ...